Articles and Abstracts
Reno, Nevada ( -- Men with advanced prostate cancer would suffer less pain and anxiety and would be less likely to be hospitalised, if their doctors were automatically alerted to contact them when their health began to fail, a new study is aiming to show.

Prostate cancer disproportionately affects racial and ethnic minority populations. Reasons for disparate outcomes among minority patients are multifaceted and complex, involving factors at the patient, provider, and system levels.

Conference Coverage
Conference Highlights Written by Physician-Scientist
Presented by Emily Rencsok
The 2022 GU ASCO Annual meeting included a prostate cancer session highlighting work from Dr. Emily Rencsok and colleagues presenting the first results from IRONMAN, an assessment of patient reported outcomes in an international registry of men with advanced prostate cancer.
Presented by Ian Davis, MB BS PhD FRACP FAChPM
Dr. Ian Davis briefly showed some of the progress that has been made with the IRONMAN study, an International Registry for Men with Advanced Prostate Cancer. This registry also includes molecular subtyping and patient-reported outcome measures (PROMs).
Presented by Alicia Morgans, MD
Dr. Morgans presented the IRONMAN project, which is the international registry for men with advanced prostate cancer. There are an estimated 1.3 million new cases of prostate cancer and 359,000 prostate cancer deaths globally each year. This is a rapidly evolving clinical landscape and there is variability in guidelines and clinical practice in advanced disease.